Loading...
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
BACKGROUND: Despite major improvements in the perioperative outcome of pancreas surgery, the prognosis of pancreatic cancer after curative resection remains poor. Adjuvant chemotherapy increases disease-free and overall survival, but this treatment cannot be offered to a significant proportion of pa...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3176241/ https://ncbi.nlm.nih.gov/pubmed/21831266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-346 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|